Feature

Blood cancer patients, survivors hesitate over COVID-19 vaccine


 

Need for clear messaging

To counter vaccine hesitancy, the authors suggest there is a need for clear, consistent messaging targeting patients with cancer that emphasize the risks of COVID-19 and underscore vaccine benefits.

Dr. Conti pointed out that patients with blood cancer are, in fact, being given preferential access to vaccines in many communities, although this clearly doesn’t mean patients are willing to get vaccinated, as she also noted.

“We need both adequate supply and strong demand to keep this vulnerable population safe,” Dr. Conti emphasized.

The Leukemia & Lymphoma Society plans to repeat the survey in the near future to assess patients’ and survivors’ access to vaccines as well as their willingness to get vaccinated.

The authors have reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Five-day course of oral antiviral appears to stop SARS-CoV-2 in its tracks
MDedge Hematology and Oncology
Potential COVID-19 variant surge looms over U.S.
MDedge Hematology and Oncology
Call to action on obesity amid COVID-19 pandemic
MDedge Hematology and Oncology
Missed visits during pandemic cause ‘detrimental ripple effects’
MDedge Hematology and Oncology
FDA authorizes first molecular at-home, OTC COVID-19 test
MDedge Hematology and Oncology
CDC data strengthen link between obesity and severe COVID
MDedge Hematology and Oncology
Delay surgery by 7 weeks after COVID-19 diagnosis, study shows
MDedge Hematology and Oncology
Inpatient sodium imbalances linked to adverse COVID-19 outcomes
MDedge Hematology and Oncology
First pill for COVID-19 could be ready by year’s end
MDedge Hematology and Oncology
Don’t delay: Cancer patients need both doses of COVID vaccine
MDedge Hematology and Oncology